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Abstract
The relative biological effectiveness (RBE) concept is commonly used in 
treatment planning for ion beam therapy. Whether models based on in vitro/ 
in vivo RBE data can be used to predict human response to treatments is an open 
issue. In this work an alternative method, based on an effective radiobiological 
parameterization directly derived from clinical data, is presented. The method 
has been applied to the analysis of prostate cancer trials with protons and 
carbon ions.
Prostate cancer trials with proton and carbon ion beams reporting 5 year-
local control (LC5) and grade 2 (G2) or higher genitourinary toxicity rates 
(TOX) were selected from literature to test the method. Treatment simulations 
were performed on a representative subset of patients to produce dose and 
linear energy transfer distribution, which were used as explicative physical 
variables for the radiobiological modelling. Two models were taken into 
consideration: the microdosimetric kinetic model (MKM) and a linear 
model (LM). The radiobiological parameters of the LM and MKM were 
obtained by coupling them with the tumor control probability and normal 
tissue complication probability models to fit the LC5 and TOX data through 
likelihood maximization. The model ranking was based on the Akaike 
information criterion.
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Results showed large confidence intervals due to the limited variety of available 
treatment schedules. RBE values, such as RBE = 1.1 for protons in the treated 
volume, were derived as a by-product of the method, showing a consistency 
with current approaches. Carbon ion RBE values were also derived, showing 
lower values than those assumed for the original treatment planning in the target 
region, whereas higher values were found in the bladder. Most importantly, 
this work shows the possibility to infer the radiobiological parametrization for 
proton and carbon ion treatment directly from clinical data.
Keywords: RBE, ion beam therapy, treatment planning
(Some figures may appear in colour only in the online journal)
1. Introduction
The adoption of ions into radiation therapy (RT) aims at improving the physical selectivity 
of the irradiation, characterized by a favorable depth-dose profile (the Bragg curve). In addi-
tion, heavy ions offer an even greater efficacy for tumor treatments thanks to the enhanced 
biological effect of their high linear energy transfer (LET). The knowledge of the radiobiol-
ogy properties of ion beams, necessary in treatment planning systems (TPSs), is expressed 
through the evaluation of the relative biological effectiveness (RBE). The purpose of the RBE 
determination is to help in prescribing the appropriate photon-equivalent dose, here referred 
to as RBE weighted dose (RWD), DRBE = D ×RBE, for which the radiation-oncologists have 
accumulated a wider clinical experience.
The complexity in measuring relevant biological effects to produce accurate mathematical 
models that link dose and LET spectra to clinical response remains one of the main problems. 
Amongst clinical centers, the RBE evaluation has been based mainly on in vitro and in vivo 
cell survival data. It is assumed that the RBE systematics found for in vitro and in vivo also 
remain true for clinical data, thus permitting the use of these estimates as surrogate of the 
‘clinical RBE’ to predict the clinical treatment outcome. Following the linear-quadratic (LQ) 
formalism, the initial RBE (α/αX) after ion beam irradiation mainly depends on the αX/βX ratio 
for the reference radiation (Koike et al 2002, Friedrich et al 2012b). The reduction of the 
required input information to the αX/βX ratios also increases the range of applicability, since 
this ratio is known for many tumor and normal tissues. These assumptions fill a knowledge 
gap between the in vitro/in vivo experimental and clinical RBE determinations.
Several different approaches are used in clinical settings to address the RBE evaluation of 
ion beams. In the case of proton beams, the RBE variation observed from in vivo studies is 
small enough to assume a constant value of 1.1 relative to a MV photon beam (Paganetti et al 
2002) according to the ICRU Report 78 recommendations (ICRU 2007). Recent studies have 
suggested that the experimentally observed deviations from RBE = 1.1 (Petrović et al 2010, 
Calugaru et al 2011) could produce clinically discernible effects. These should be considered 
especially for single-field treatments and when organs at risk (OARs) are located immediately 
distal to the Bragg peak (Tilly et al 2005, Frese et al 2011, Grassberger et al 2011, Giantsoudi 
et al 2013, Grun et al 2013). However, the clinical relevance of these RBE variations is still a 
matter of debate (Sethi et al 2014).
For carbon ion-beam therapy with carbons the RWD has to be explicitly evaluated and 
optimized in the planning procedure (IAEA 2008). This is generally a difficult task due to 
the manifold dependencies of RBE (particle type, kinetic energy, fractionation scheme, dose-
delivery time structure, cell or tissue type) and to the complex mixed radiation field in the 
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patient during the irradiation. The few institutes using carbon ion beams for treatment have 
taken different approaches for calculating the effective dose. At Heavy Ion Medical Accelerator 
in Chiba (HIMAC) and Hyogo Ion Beam Medical Center (HIBMC) extensive beam-specific 
in vitro cell-survival measurements are used to model the RBE as a function of depth, LET 
and/or kinetic energy. The absolute dose level is determined by adjusting the RBE for carbon 
ions at the distal part of the spread out Bragg peak (SOBP) to coincide with the RBE used 
in neutron therapy (Kanai et al 1997, Kanai et al 1999, Kagawa et al 2002). In particular, 
the design of the SOBP at HIMAC is based on in vitro measurements of the human salivary 
gland (HSG) tumor cell line as end-point surrogate (Matsufuji et al 2007). Other approaches 
are based on the development and implementation of more comprehensive biologic models, 
such as the local effect model (LEM) (Scholz and Kraft 1996, Scholz et al 1997, Elsässer 
and Scholz 2007, Friedrich et al 2012a) and the microdosimetric-kinetic model (MKM) 
(Hawkins 1998, Hawkins 2003). Although the mechanics of the models are different, their 
basic assumptions are similar and they have been shown to produce similar output (Kase 
et al 2008). In particular, the European facilities, such as Heidelberg Ion-Beam Therapy 
Center (HIT) and Centro Nazionale di Adroterapia Oncologica in Pavia (CNAO), use the 
LEM with a parametrization corresponding to a unique representative cell line, with an αX/βX 
ratio fixed at 2 Gy, derived from mice brain in vivo measurements (Krämer and Scholz 2000, 
Jäkel et al 2007, Fossati et al 2012). The LEM was also benchmarked in retrospective analy-
sis to evaluate clinical dose-effect probabilities from the dose volume histograms (DVHs) of 
treated patients (Schlampp et al 2011).
Several issues can be easily identified within the present RBE-based approaches. Large 
uncertainties are involved in the currently in vitro RBE estimations, which were fitted to set 
of experimental cell survival data for protons and carbon ions. Inaccuracy in RBE estimation 
remains the main source of uncertainty in the prescribed dose, in particular for carbon ion 
therapy (Durante and Loeffler 2010, Jones et al 2011). These fluctuations are irreducible: 
the RBE values from in vitro experiment in the past 50 years show a high variance and this 
spread cannot be reduced by repeating similar experiments (Friedrich et al 2012b, Loeffler 
and Durante 2013). There is also the fundamental question about the RBE translatability from 
in vitro to in vivo conditions. For example, it is well known that RBE variations tend to be 
smaller for in vivo systems, in particular the dependence on dose, i.e. the increasing of RBE 
with decreasing dose, appears to be weaker in vivo compared to the in vitro data (Paganetti 
et al 2002). Moreover, the type of cell lines used in these in vitro/in vivo experiments may 
not be representative of the different types and stages of tumors and healthy tissues involved 
in treatments. In this regard the RBE value for late-reacting normal tissues and slow-growing 
tumors could be different (and higher) for acute-reacting normal tissues and rapidly grow-
ing tumors (Jones et al 2011). Furthermore, the reference biological parameterization used 
in photon radiotherapy (e.g. the LQ parameters αX and βX) has a large variance, introducing 
an additional layer of uncertainty in the RBE based approaches (Bentzen and Joiner 2009, 
Bentzen et al 2010, Deasy et al 2010, Jackson et al 2010).
The aim of this work is to present an alternative method to the standard RBE-based treat-
ment planning approaches, depending on the evaluation of the absolute biological effect that 
can be linked more directly to the clinical outcome of ion beam treatments. We evaluated the 
biological effects at the cell level via specific radiobiological models in the framework of the 
standard LQ model. Tumor control probability (TCP) and normal tissue complication prob-
ability (NTCP) have been coupled to the radiobiological models and used to infer the optimal 
radiobiological parameters for each specific end-point from the clinical data. The LQ param-
eters obtained may vary inside the patient, depending on the complex anatomical geometry of 
the patient, the mixed-LET spatially-varying quality of the irradiation and the specific tissues/
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endpoints, affecting the RWD dose distribution. RBE distributions have been obtained as a by-
product of the general procedure to make comparisons with the current standard approaches 
reported in literature. The method has been tested for the treatment of prostate carcinoma with 
protons and carbon ions beam. More specifically, concerning the toxicity rates, late bladder 
complications were analyzed.
2. Materials and methods
2.1. General workflow
On the left side of the flowchart in figure 1, the standard RBE-based procedure commonly 
followed in treatment planning for ion beam therapy is shown while the workflow on the right 
summarizes the alternative procedure proposed in this work. In the first step the absorbed dose 
D and LET distributions were computed based on representative patients and treatment defini-
tions. The estimation of the biological and clinical effects was performed in the following two 
steps, namely the ‘radiobiological’ evaluation, i.e. the evaluation of the probability to observe 
a specific absolute effect at the cell level (such as cell survival of tumor or healthy tissues) and 
TCP and NTCP evaluations. By comparing the predicted TCP and NTCP with the observed 
clinical outcomes in terms of patient survival (or local control, or biochemical relapse) and 
toxicity, it was possible, through a fitting procedure, to infer the optimal effective parametri-
zation of the biological and clinical models for ion treatments. These steps are detailed in the 
following sections.
2.2. Clinical data and treatment definition
To illustrate and test the method, an exemplifying application using a series of published clini-
cal datasets describing the dose response of patients treated with proton and carbon ion beams 
was performed. For this purpose, a literature search using PubMED, aimed at identifying 
Figure 1. On the right-hand side, the flowchart outlining the proposed treatment 
planning procedure is shown. On the left-hand side the standard approach is displayed.
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relevant published prostate cancer trials with ion beams, was carried out. Only papers pro-
viding the necessary details to implement the treatment simulations, such as delivery type, 
treatment schedule, beam setup, optimization method, RBE and number of patients, were con-
sidered. The designed papers report clinical trials performed in HIMAC and HIBMC (table 1) 
(Mayahara et al 2007, Okada et al 2012). The selected data consist of three groups of patients 
identified by their treatment protocols, one with proton and two with carbon ion beams, the 
latter corresponding to two different fractionation schemes. As surrogate of TCP we focused 
on the 5 year biochemical relapse-free survival (bRFS), while for the NTCP we considered G2 
or higher bladder (genitourinary) toxicity (TOX).
2.3. Patient model and reference treatment planning
The proposed evaluation of the TCP/NTCP relies on the knowledge of the dose and LETd 
distributions of the individual patients. Since individual patient data were not available for this 
study, an approximation was introduced using a representative patient set. Computed tomog-
raphy (CT) data from six representative prostate cancer patients and corresponding contoured 
structures were obtained from a clinical database and used. The six patients were assumed 
to be representative of the inter-patient anatomical variability that could be expected for a 
generic class of patients. Following the latter premise, the same six patients CT and structure 
data sets were used to evaluate the dose and LETd distributions for each group (defined in the 
previous section), using the corresponding irradiation setups reported in table 1. This assump-
tion is in particular acceptable for the purpose of the paper, the primary goal of which is to 
demonstrate the feasibility of the method and to illustrate an exemplary application.
The reported biological dose prescriptions and beam setup were used to implement the 
treatment planning simulations in which patients were irradiated with proton with Df = 2 GyE 
dose per fraction (Mayahara et al 2007) and with carbon ions with Df = 3.15 and 3.6 GyE 
dose per fraction (Okada et al 2012). In the case of the prostate, the standard technique for 
proton treatments consisted of two lateral opposed fields, while for carbon ion, three beams 
were used (2 lateral and one anterior-posterior). The TPS PlanKIT, developed and validated by 
INFN/IBA for proton and carbon ion beam therapy (Russo et al 2014), was used to optimize 
the treatment plans and to evaluate the putative dose and dose averaged LET (LETd) distribu-
tions in the patients. In the planning simulations a computing grid voxel size of 3 × 3 × 3 mm3 
was used.
Concerning the proton treatments, plans were optimized assuming a constant RBE = 1.1 in 
the whole patient (Mayahara et al 2007). In the case of carbon ions, the plans were biologi-
cally optimized using the MKM. The reference MKM parametrization was selected in order 
to reproduce in vitro cell survival data extracted from the Particle Irradiation Data Ensemble 
Table 1. Clinical data of prostate cancer trials with proton and carbon ion 
irradiations. In the case of protons, two laterally opposed fields were used, 
while for carbon ions one anterior-posterior port and a pair of lateral ports 
were used. Nf and Np are the number of fractions and the number of patients, 
respectively.
Reference Ion Df [GyE] Dtot [GyE] Nf RBE Beam setup Np bRFS TOX
Mayahara2007 1H 2 74 37 1.1 2 fields 287 81%(5yr) 1% G3
Okada2012 12C 3.15 63 20 3a 3 fields 216 90.2%(5yr) 6.5% G2
Okada2012 12C 3.6 57.6 16 3a 3 fields 198 88.5%(5yr) 2% G2
a In distal SOBP.
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(PIDE) database provided by the Gesellschaft für Schwerionenforschung (GSI) (Friedrich 
et al 2012b) and corresponding to a hypothetical tissue type with ratio R = αX/βX = 3 Gy for 
late responding tissues. We verified that with this parametrization we were able to reproduce a 
RBE = 3 in the distal part of the SOBP as reported in Okada et al (2012). The planning target 
volume (PTV) tolerance margins were adjusted until isodoses and PTV/bladder DVHs were 
similar to those reported in Mayahara et al (2007) and Okada et al (2012). The treatment 
planning evaluations described in this section are identified in this work as ‘reference plans’. 
An example of the obtained dose and LETd distributions of a treatment is shown in figure 2.
2.4. Radiobiological modelling
The first step in biological modelling, leading to the evaluation of the probability of specific 
biological endpoints at the voxel level, is outlined in the context of the LQ model:
 α β= − −p D D D( , LET ) exp ( (LET ) (LET ) )d d d 2 (1)
where LETd, evaluated by the TPS, represents the dose-averaged LET in a specific voxel and 
was used as a surrogate for spectral characteristics of the energy deposition.
Regardless of the complex dependence between RBE and LET, it has been demonstrated 
that the LETd, together with the dose, can be effectively used to completely characterize the 
biological effect of the irradiation. In fact, several in vitro and in vivo studies have proven 
that, for a given endpoint, the proton RBE values show a linear dependence on LET in the 
dose and energy ranges clinically adopted (Paganetti et al 2002, Carabe et al 2012). A simple 
Figure 2. Example of dose (panels (a) and (c)) and LETd (panels (b) and (d)) 
distributions evaluated using the PlanKIT TPS for one patient irradiated with proton 
with Df  =  2  GyE dose per fraction (panels (a) and (b)) and carbon ion beams with 
Df = 3.6 GyE (panels (c) and (d)). The white arrows indicate the main beam-ports and 
their directions.
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relationship was also used for proton in the range between 1–20 keV µm−1 to perform treat-
ment planning simulations (Wilkens and Oelfke 2004a, 2004b). A strong linear correlation 
between RBE and LETd was also found in the case of carbon ions for values up to 90 keV µm−1 
(Ando and Kase 2009).
2.4.1. Proton modelling In this study, a linear model (LM), that assumes a linear relation 
between α and the LETd, was adopted for protons
 
α α
β β
= + ×
=
m LETdLM 0
LM
(2)
where α0 is the linear parameter of LQ model in the limit LET → 0, while βLM is assumed to 
be independent of LET (Frese et al 2011, Wilkens and Oelfke 2005). θ = (α0, m, β) represents 
the ‘biological’ free parameters of the LM to be adjusted via the likelihood maximization to 
reproduce the experimental clinical data.
In the present investigation two versions of the LM were considered. In the first approach, 
denoted as LM1, we kept α0 as a free parameter, while setting m = 0 and β = βX to the reference 
radiation value. Neglecting the LETd dependence in the LM1 implies that a constant RBE is 
used along the specific organ/tissue. Conversely, in LM2, the LETd modulation within the 
treated volume was explicitly accounted for by using m ≠ 0 as a free parameter to be adjusted 
via the likelihood maximization and setting (α0, β) = (αX, βX), i.e. to the values of the refer-
ence radiation. The latter assumption implies that RBE → 1 when LETd → 0. Both LM1 and 
LM2 were used to describe the biological response of the clinical target volume (CTV) and 
the bladder volumes for which the parameters were adjusted independently. A test was also 
performed to verify if the parameter m can be considered tissue independent as was proposed 
in Frese et al (2011). The reference radiation LQ parameters used for the tumor and blad-
der are summarized in table 2. These values were derived from the 50% response dose D50, 
the maximum normalized value of the dose-response gradient γ and the ratio R = αX/βX, as 
reported in Mavroidis et al (2013).
2.4.2. Carbon ion modelling. Benchmarking of the MKM for carbon ion irradiation showed 
that the model agrees well with monoenergetic in vitro cell measurements (Kase et al 2008). 
The model was also used in more complex clinical treatment planning studies (Inaniwa et al 
2010) and hence it is another good candidate for the present analysis. A reformulation of the 
MKM in terms of LETd was used (named cMKM) for the fitting procedure. According to the 
cMKM the LQ parameters were calculated as
 
α α β γ γ
γ
β β
= − − −
=
1 exp ( ( ) )n
n
cMKM
0 0
cMKM
(3)
Table 2. Values of the parameters used for the reference x-ray radiation 
(Mavroidis et al 2013). Note: D50 is the 50% response dose, γ is the maximum 
normalized slope of the dose-response curve and s is the relative seriality 
parameter.
Type D50 [Gy] γ
α
β
X
X
 [Gy] αX [Gy−1] βX [Gy−2] s
CTV(prostate) 62 4 2 0.0906 0.0453 —
Bladder 80 3 3 0.0639 0.0213 0.18
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where α0 is the linear parameter of LQ model in the limit LET → 0, while β is assumed LET 
independent. In this formulation β0 is an internal parameter of the model and in general β ≠ β0. 
γ = γ(Rd, LETd) and γn = γn(Rn, LETd) are the dose-averaged specific energies delivered in a 
single event within the domain and cell nucleus, respectively. Rd and Rn are the radii of the 
domain and cell nucleus, respectively and, together with α0, β0 and β, represent the biological 
parameters θ of the cMKM. The averaged specific energies were evaluated using an amor-
phous track structure model (Kase et al 2008), assuming the irradiation was composed of 
representative particles with charge Z = 6 and LET = LETd.
Two versions of the cMKM were considered. In the first one, denoted as cMKM1, we 
kept β0 as the only free parameter to be determined via the likelihood maximization, while 
we set α0 = αX, β = βX, equal to the LQ parameters of the reference radiation (see table 2). 
Rn = 3.99 µm and Rd = 0.37 µm were also kept fixed. The latter values correspond to the val-
ues used in the reference MKM parametrization. Within this version of the model, the RBE is 
forced to be 1 in the limit of LETd → 0. The choice to use β0 as the adjustable free parameter 
was dictated by a sensitive analysis of the model. By changing this parameter it is possible to 
effectively modulate the steepness of the α (LETd) response curve (see for example figure 3), 
the latter having the maximum correlation with the TCP and NTCP estimations and hence 
with the tissue characterization. In the second version of the model, indicated with cMKM2, 
Figure 3. RBEα = α/αX versus LETd distribution, calculated at the voxel level for the full 
body, in two fictitious treatments: a prostate cancer (two opposing irradiation fields) and 
a pediatric brain tumor case (three coplanar irradiation fields on the coronal plane). Two 
radiobiological parametrizations were used in both cases corresponding to αX/βX ratios 
R = 3 Gy and R = 10 Gy. The cloud of points represents the evaluation performed using 
the MKM and the complete LET spectra for each voxel of the irradiated volumes, while 
the continuous lines represent the cMKM evaluations. The circled regions represent the 
loci of the planning target volume (PTV) for the prostate (dashed line circle) and brain 
tumor (solid line circle) targets.
A Cometto et al
7401
Phys. Med. Biol. 59 (2014) 7393
two free adjustable parameters were considered, namely β0 and β, while keeping α0 = αX, 
the reference radiation value (table 2) and Rn and Rd equal to the in vitro estimations. Both 
cMKM1 and cMKM2 were used to describe the biological response of the CTV and the blad-
der, using independent parametrizations.
2.4.3. LETd dependence analysis. We verified by comparing the LM and cMKM evaluations 
with the MKM simulations performed using the complete spectra of the particles, including 
secondary ions, that the biological effect is mainly dependent on LETd, with little influence 
on the full LET spectra. It is possible to reproduce the effect predicted by the complete evalu-
ations via a proper choice of the biological parameters θ (see figure 3). We also determined, 
through simulations of different irradiation conditions, such as variations in beam-setup and 
patient anatomy, that the biological parametrization of the LM and the cMKM is factorized 
with respect to the LETd dependence. This means that, within these models, the biologi-
cal parametrization of the tissue does not depend on the specific ballistic of the irradiation, 
but only reflects the biological properties of the tissue (3). The set of biological parameters 
derived from the fitting procedure on a specific training set can be effectively used for predic-
tive analyses in different irradiation conditions, associated to different LETd distributions.
2.4.4. RBE evaluation. The LQ parameters evaluated according to the LM and cMKM mod-
els can be used efficiently to determine RBE values using a formalism that accounts for RBE 
variation over dose, LETd and tissue type (Carabe-Fernandez et al 2007, Carabe-Fernandez 
et al 2010).
 
⎛
⎝⎜
⎞
⎠⎟β α=
− + + +( )
D
R D
D
RBE ( , LET )
1 1 4 (LET )
2
d
X d
D
R
2
(4)
where the R is the reference radiation ratio αX/βX, while the quadratic parameter β = βX for the 
ion irradiation is assumed to be equal to the one of the reference radiation.
2.5. Clinical response models
The models used in this study to quantify the TCP/NTCP are based on Poisson distribution 
assumptions (Munro and Gilbert 1961) taking into account also the tumor characteristic and 
the organ architecture, respectively (Källman et al 1992)
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where the product is over the voxels i in volume V(j), each of them with sub-volume dv, j is 
the index pointing to the specific tissue/organ and s(j) is the relative seriality parameter of the 
organ in consideration. The expected number of survived clonogens ni
j( ) was calculated as
 ∏θ γ γ θ= ∣ = ∣
=
n n D N e p D N( , LET , , ) exp ( ) ( / , LET )i
j
i i f
j j j
f
N
i f i
j( )
d,
( ) ( ) ( )
1
d,
( )
f
(6)
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where γ(j) is a parameter associated with the density of clonogens prior to irradiation, Di 
is the total dose deposited in the i-th voxel, Nf is the number of treatment fractions. The 
θ∣p D N( / , LET )i f i jd, ( )  are the probabilities of the specific endpoint at the cellular level, as 
defined in equation (1) and are evaluated using the LM (equation (2)) or the cMKM (equation 
(3)). In this formulation, the clonogen repopulation during treatment is neglected and the full 
repair between fractions has been also assumed, i.e. the fractions are completely uncorrelated.
The θ(j) is the set of free biological parameters for the specific tissue/organ, according to the 
specific radiobiological model, θ(j) = (α0, m, β)(j) for the LM and θ(j) = (α0, β0, Rn, Rd, β)(j) for 
the cMKM. Since the parameters γ and s are assumed to be radiation type independent, they 
were kept fixed to the values reported in literature from x-rays irradiations, γ = 4 for the tumor 
and γ = 3 and s = 0.18 for the bladder (Mavroidis et al 2013) (see table 2).
Poisson-based models were used in the present analysis since they are able to evaluate 
the individual response to the irradiation and to directly use the cell survival probability 
computed at the voxel level. Population response can be achieved by integrating the response 
over different individuals (described in the following). Other models that effectively describe 
a population response have been proposed, e.g. the Marsden model for the TCP (Webb and 
Nahum 1993) or equivalent uniform dose (Niemierko 1997) EUD-based models, for both 
TCP (Stavrev et al 2010) and NTCP (Mohan et al 1992, Deasy 2000). However, they need 
to be recast properly in order to provide the radiobiological coupling we need in our analy-
sis, taking into account the spatially varying radiosensitivity due to the non-uniform LET 
distribution.
Due to the sparseness of the available data, the simplifying assumption that the biologi-
cal parameters do not display inter-patient variability was also knowingly made. In other 
words, the inter-patient variability of the response is assumed to be solely associated to the 
variability of dose and LETd distributions among patients and that it does not depend on 
the variability of the inherent biological parametrization. To account for inter-patient vari-
ability of θ(j), an additional set of parameters σθ j( ) will eventually be introduced in a further 
development of the model, in which the TCP/NTCP will be integrated, e.g. by means of a 
Monte Carlo sampling over the parameter distribution, characterized by an average θ(j) and 
a standard deviation σθ j( ).
2.6. Statistical analysis
The parameters θ of the LM and cMKM included in the TCP/NTCP models were used as 
adjustable free parameters to reproduce experimental tissue/organ endpoint (bRFS and TOX 
data, respectively). Considering the binary nature of the outcome (local recurrence or the 
occurrence of a complication), the most accurate fitting method is the maximum likelihood 
estimation and it corresponds to maximize
 ∑θ π θ π θ∣ = ∣ + − − ∣LL e e D e D( LET , ) · ln ( ( , LET )) (1 ) · ln (1 ( , LET ))d k
k
k k k d k k k dk k k (7)
where θ θ∣ =LL D e LL( , LET , ) ( )k kdk  indicates the logarithm of the likelihood, ek is the binary 
outcome (0 or 1) for patient k, π θ π θ∣ =D( , LET ) ( )k k kdk  is the estimate of the TCP/NTCP for 
the parameter set θ (equation (5)). Dk and LETdk represent the complete three-dimensional 
dose and LETd distributions found in patient k.
Since individual patient data were not available for this study, equation (7) could not be 
directly applied and a population-based statistics was introduced. Analytical formulations of 
TCP/NTCP for a population of patients have been proposed in literature to account for the 
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heterogeneity of the model parameters and of the dose among the patients (see for example 
Carlone et al (2006), Schinkel et al (2007), Stavrev et al (2001, 2010) and Webb and Nahum 
(1993)). In our case the population response was modeled by explicitly evaluating the individ-
ual TCP/NTCP over the representative patient set and then averaging the results. The groups 
were identified based on similarity of treatment with respect to the predictors in the model, 
corresponding to the treatment setups reported in table 1. Then the likelihood function to be 
optimized becomes:
 ∑θ Π θ Π θ= + − −
=
LL r n r( ) · ln ( ( ) ) ( ) · ln (1 ( ) )
l
N
l l l l l
1
(8)
where nl and rl indicate the number of patients and responders (controlled patients/patients 
with complications) in group l, respectively. The summation is performed over the groups of 
patients, N = 1 in the case of protons and N = 2 in the case of carbon ion treatments. Πl(θ) is the 
average TCP/NTCP over the set of representative patients obtained when the group-specific 
treatment setup is applied. Thus, for each group
 ∑θ π π θΠ = ⟨ ⟩ =′
′ ′=
′
′
N
( )
1
( )k
l
k
l
k
N
k
l
l
( )
( )
1
( )
k
l( )
(9)
where k′ is the representative patient index and =′N 6kl( )  is the number of representative 
patients in the l-th group.
95% one-dimensional confidence intervals (CI) and correlated confidence regions (CR) 
were obtained by exploring the value of LL in the neighborhood of its maximum and thus 
reproducing the entire iso-surfaces defined by
 χ= −LL LLmax ( ) 1
2
(0.05)hCI
2 (10)
where h is the number of free parameters. Explicitly:
 θ θ= ∣ ⩽LL LLCR { ( ) }CI (11)
and the corresponding confidence bands (u, l) for a derived quantity, such as the RBE, are 
defined as
 
θ
θ
= ∣
= ∣
θ
θ
∈
∈{ }
{ }D D
D D
RBE ( , LET ) minRBE ( , LET )
RBE ( , LET ) maxRBE ( , LET )
l d d
u d d
CR
CR
(12)
with RBEl ⩽ RBE ⩽ RBEu. Following a principal component analysis approach, a possible 
linear transformation of the free parameters of the cMKM2, (β, β0) → (β, β1), was identified to 
reduce the strong linear correlation. The transformation is β1 = β0 + k(β* − β) where β* is the 
value of β corresponding to the maximum likelihood and k is an angular coefficient obtained 
from the eigenvector analysis of the correlation matrix.
The Akaike information criterion (AIC) (Akaike 1974) was used to compare the accuracy 
of the different models weighting also their complexity in terms of number of free parameters. 
AIC is mathematically expressed as follows:
 = −h LLAIC 2 2max ( ) (13)
The lower the AIC number, the better the model for describing a given dataset.
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2.7. Degeneration of the solutions
One of the major limitations of the described method can be found in the possible degenera-
tion of the solutions in the maximization of equation (8). It is likely that, due to the limited 
amount of available clinical data, it is impossible to properly fix all the parameters of the 
model. More precisely, treatments with different dose per fraction are required to univocally 
identify the LQ parameters α (LETd) and β. Furthermore, in order to better discriminate the 
parameters expressing the LETd dependence, such as m for the LM and β0 for the cMKM, dif-
ferent irradiation modalities (beam setups) and dose/fraction are necessary. A general method 
to resolve this potential degeneration is to modify equation (7) using a Bayesian framework 
by adding an a-priori likelihood potential p0(θ) to include the probabilistic information from 
the in vitro parametrization
 θ θ θ′ ∣ = ∣ +LL D e p D e p( , LET , ) ln ( ( , LET , ) ) ln ( ( ))k d k k d k 0k k (14)
where the probability distribution θ∣p D e( , LET , )k d kk  is the one used to derive the likelihood 
in equation (7) and p0(θ) is obtained from the analysis of in vitro data. To account for the het-
erogeneous data from in vitro experiments, a bootstrap method can be used to estimate p0(θ). 
The Bayesian approach embodied in equation (14) is not included in the present study, but it 
is introduced here as a natural extension of the implemented method.
3. Results
Typical dose and LETd distributions for proton- and carbon ion-based RT are reported in 
figure 2, for a single patient. The dose versus LETd distributions of the complete set of rep-
resentative patients are reported in figure 4. The single peak found in the target irradiated 
with protons is due to the small LET variance and to the usage of a constant RBE = 1.1 in the 
inverse planning procedure. The variability and the strong anti-correlation between dose and 
LETd observed in the target irradiated with carbon ions, is due to the approximate proportion-
ality RBE ∝ LETd and the uniform equivalent dose constraint used in the inverse planning. 
The analyzed cases show the typical spread observed in the dose volume histograms (DVHs) 
when a patient population is considered. While similar patterns among patients are observed 
in distributions inside the tumoral target, an irregular behavior is found in the bladder volume, 
due to the anatomical variance within the population.
3.1. Prostate treatments with protons
When considering the proton-based treatments using a single trial (only one fractionation 
scheme), only one parameter, α0, m or β, can be determined when the LM is used. The radio-
biological parameters α0 and m (for LM1 and LM2 respectively) obtained from the likelihood 
maximization for target and bladder, with their CI, max(LL) and AIC values are reported in 
table 3. In the same table, the values corresponding to the reference planning, in which a 
constant RBE = 1.1 was used, are also reported for comparison. In figure 5, an example of the 
likelihood profiles obtained in the case of LM1 is displayed. In the same figure the estimates 
of the bRFS and the G3 toxicity together with their experimental values are also shown.
Exploiting the radiobiological parameters inferred from the clinical data, we re-calculated 
the RBE distributions in the target and the bladder via equation (4) for the complete patient 
set. The RBE volume histograms (RVH) of the re-calculated RBE distributions, employing 
both LM1 and LM2, are pictured in figure 6. In the same figure the results obtained from the 
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Figure 4. Dose versus LETd distributions for the full set of representative patients, 
calculated at the voxel level in the CTV (panels (a) and (c)) and in the bladder (panels 
(b) and (d)), for proton irradiations (panels (a) and (b)) and carbon ion irradiations 
(panel (c) and (d). Each dot represents the values of dose and LETd found in a single 
voxel belonging to a specific VOI. Marginal distributions are also included in the plots. 
Different colours are associated with different patients.
reference planning (RBE = 1.1) are also reported for comparison. The results for a specific 
patient are reported in figure  7, where an estimation of the corresponding CBs via equa-
tion (11) is also shown.
An average RBE = 1.1 was found, with an RBE < 1.1 in the target and RBE > 1.1 in the 
bladder. The modulation of RBE reported in panel (a) and (b) of figure 6, is due exclusively 
to its dose dependence (see equation (4)), since in LM1 the LETd dependence is neglected, 
α (LETd) = α0. The spatial gradient of the RBE is larger when using an explicit LETd depend-
ence for the α parameter, as in LM2, where values up to 1.8 in small volumes of the bladder 
were found (figure 6, panels (c) and (d)).
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3.2. Prostate treatments with carbon ions
In the case of carbon-based RT, two trials were available allowing the determination of up to 
two parameters of the cMKM. The parameters β0 for CTV and bladder and the corresponding 
CI, max(LL) and AIC values, obtained from the model cMKM1 used to simultaneously fit two 
Table 3. Radiobiological model parameters for the proton-based treatments. 
CI, AIC and max(LL) values are also reported. The last two entries of the 
table  correspond to consider the LM2 simultaneously for the CTV and the 
bladder. Note: the likelihood values were normalized removing a binomial 
factor common to all models.
Model Organ/VOI Parameter Value CI(95%) AIC max(LL)
Reference CTV RBE 1.1 Fixed 316.95 −158.47
Reference Bladder RBE 1.1 Fixed 33.58 −16.79
Reference CTV, bladder RBE 1.1 Fixed 350.52 −175.26
LM1 CTV α0 [Gy−1] 0.1026 0.0988, 0.1067 282 −140
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
0 Fixed
β [Gy−2] 0.0453 Fixed to βX
LM1 Bladder α0 [Gy−1] 0.0835 0.0747, 0.0923 34 −16
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
0 Fixed
β [Gy−2] 0.0213 Fixed to βX
LM2 CTV α0 [Gy−1] 0.0906 Fixed to αX 281.09 −139.54
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
0.0034 0.0023, 0.0045
β [Gy−2] 0.0453 Fixed to βX
LM2 Bladder α0 [Gy−1] 0.0639 Fixed to αX 34.14 −16.07
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
0.0053 0.0029, 0.0078
β [Gy−2] 0.0213 Fixed to βX
LM2 CTV, bladder α0 [Gy−1] (CTV) 0.0906 Fixed to αX 315.24 −155.62
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
 (CTV) 0.0034 0.0023, 0.0045
β [Gy−2] (CTV) 0.0453 Fixed to βX
α0 [Gy−1] (blad.) 0.0639 Fixed to αX
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
 (blad.) 0.0054 0.0029, 0.0078
β [Gy−2] (blad.) 0.0213 Fixed to βX
LM2 CTV, bladder α0 [Gy−1] (CTV) 0.0906 Fixed to αX 315.37 −156.68
β [Gy−2] (CTV) 0.0453 Fixed to βX
α0 [Gy−1] (blad.) 0.0639 Fixed to αX
β [Gy−2] (blad.) 0.0213 Fixed to βX
m 
⎡
⎣⎢
⎤
⎦⎥
μm
GykeV
0.0038 0.0027, 0.0048
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different trials, corresponding to Df = 3.15 Gy and Df = 3.6 Gy, are reported in table 4. The 
simultaneous determination of β0 and β was performed using the cMKM2 to concurrently fit 
the two trials; the corresponding values for CTV and bladder are also reported in the same 
table. The likelihood landscape for the radiobiological parameters and the corresponding CRs 
are reported in figure 8. The radiobiological parameters for the CTV obtained from cMKM1 
and cMKM2 are similar, while the AIC value is slightly lower in the case of cMKM1, giving 
preference to the latter. Negative β estimates were obtained for the bladder in the case of the 
cMKM2, whereas, by construction, the cMKM1 employs positive values of β. In this case the 
cMKM1 AIC is slightly higher with respect to cMKM2.
The RBE and equivalent dose for target and bladder have also been re-calculated with the 
optimized parameter sets, using both the cMKM1 and cMKM2 parametrization. The volume 
Figure 5. In panel (a), examples of log-likelihood profiles obtained for the α0 parameter 
of LM1 (proton-based treatments), for the CTV and for the bladder, are reported. 95% 
CI are also represented in the plot with shaded areas. In panel (b) the corresponding 
estimates Π = 〈TCPk〉 and Π = 〈NTCPk〉, for bRFS and G3 TOX respectively, are also 
reported together with the experimental values (circles).
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histograms of the RBE and equivalent dose distributions evaluated in target and bladder, for 
the carbon-based RT trial with dose per fraction Df = 3.6 Gy(RBE), together with those the 
reference plan, are shown in figure 9.
3.3. RBE and RWD volume histogram confidence bands
The uncertainty associated with the fitted radiobiological parameters translates into an uncer-
tainty in the derived quantities, such as the RBE and the corresponding RWD. The contribu-
tion of this specific component to treatment uncertainties was calculated for all the investigated 
models using equation (12).
In figure 7 the RBE and the RWD volume histograms, evaluated for a single representa-
tive patient, are shown for both protons and carbon ions. In the same plot the 95% confidence 
bands obtained from the probability distribution of the radiobiological parameters are also 
reported (shaded area of the same color.)
An average 4% RBE uncertainty for protons was found in the target RVH, whereas for the 
bladder a 10% uncertainty in the low RBE region and 20% (LM1) and 25% (LM2) in the high 
RBE region were found. The same relative uncertainties were also found in the RWD DVHs. 
Similar results were obtained within the cohort.
In the case of carbon ion-based RT, the RBE uncertainty presents a complex behaviour. For 
the CTV, average RBE CIs of 2.5% (cMKM1) and 5% (cMKM2) were found. For the bladder, 
average RBE CIs of 8% (cMKM1) and 15% (cMKM2) were found. CIs of 2.5% (cMKM1) 
and 5% (cMKM2) for the equivalent dose, for both CTV and bladder, were also found. Similar 
results were obtained within the cohort.
Figure 6. Volume histograms of the RBE and RWD distributions for the proton-based 
RT trials, evaluated in the CTV and in the bladder for the complete set of representative 
patients. The evaluations were performed for the reference plan, the LM1 and the LM2 
radiobiological parametrizations. In panel (e) and (f) RBE = 1.1 for the reference plan 
is also reported.
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Figure 7. Log-likelihood landscape (LL − max(LL)) obtained from the analysis of two 
trials with carbon ions (Df  = 3.15 and 3.6 Gy(RBE)), using the cMKM2 parametrization. 
In panels (a) and (c) the CTV log-likelihood landscapes using the original parametrization 
(β0, β) and the transformed one (β1, β) are reported. The corresponding bladder log-
likelihood landscapes are reported in panel (b) and (d). In panel (e) is reported the CTV 
evaluation in which a fictitious trial (Df  = 8 Gy(RBE)) is used together with a real one 
(Df  =  3.15  Gy(RBE)). The blue line represents the contour encircling the 95% CR. 
The dashed lines represent LL profiles maximized for the complementary parameter: 
β β β* = β LLarg max ( ( , ) )0 0  and β β β* = β LLarg max ( ( , ) )00 .
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4. Discussion
The implemented procedure allows for an estimation of the radiobiological parameters for 
target and bladder based on the reported clinical data.
4.1. RBE and RBE weighted dose distributions
Regarding protons, an average RBE  =  1.1 was found, consistently with the current clini-
cal approach. However, in the target the predicted RBE is slightly lower than the assumed 
Table 4. Radiobiological model parameters for cMKM1 and cMKM2 (carbon 
ion based treatments). CI, AIC and max(LL) values are also reported. Note: 
the likelihood values were normalized removing a binomial factor common 
to all models.
Model Organ/VOI parameter value CI(95%) AIC max(LL)
cMKM1 CTV α0 [Gy−1] 0.0906 Fixed to αX 281.97 −139.98
β0 [Gy−2] 0.0262 0.0253, 0.0270
β [Gy−2] 0.0453 Fixed to βX
cMKM1 Bladder α0 [Gy−1] 0.0639 Fixed to αX 147.67 −72.84
β0 [Gy−2] 0.0198 0.0186, 0.0212
β [Gy−2] 0.0213 Fixed to βX
cMKM2 CTV α0 [Gy−1] 0.0906 Fixed to αX 283.84 −139.92
β0 [Gy−2] 0.0242 Correlated CR
β [Gy−2] 0.0629 Correlated CR
cMKM2 Bladder α0 [Gy−1] 0.0639 Fixed to αX 146.72 −71.37
β0 [Gy−2] 0.0342 Correlated CR
β [Gy−2] −0.1111 Correlated CR
Figure 8. Volume histograms of the RBE and equivalent dose distributions for the 
carbon-based RT trials, evaluated in the CTV and in the bladder for the complete set of 
representative patients. The evaluations were performed using the reference plan, the 
cMKM1 and the cMKM2 radiobiological parametrizations.
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RBE = 1.1; this is in agreement with some analyses and preclinical studies (see e.g. Kagawa 
et al (2002) and Paganetti et al (2002)). Conversely, the RBE values found in the bladder 
are larger than 1.1, due to the LET increase at the end of the proton range. Such values are 
consistent with experimental in vitro observations (Petrović et al 2010, Calugaru et al 2011). 
This explanation holds also in the case of LM1 where an implicit RBE-LETd dependence has 
in fact been considered by using different radiobiological parameters for target and bladder. 
In the case of LM2 analysis, where the RBE-LETd dependence is explicitly accounted for, 
hot-spots with larger RBE were found in the bladder, as expected from the high LET com-
ponents due to secondary particles in the border region of the irradiation field (Grassberger 
Figure 9. Volume histograms of the RBE and RWD evaluated for a single patient, for 
proton with models LM1 and LM2 (panels (a) and (c)) and carbon ion with models 
cMKM1 and cMKM2 (panels (b) and (d)). In the same plots the 95% confidence band 
obtained from the probability distribution of the radiobiological parameters are reported 
(shaded area). The dashed lines represents the reference values of the RBE (RBE = 1.1 
for protons and RBE = 3 for carbon ions) and of the planned equivalent dose in the CTV 
(D = 2 Gy(RBE) for protons and D = 3.6 Gy(RBE) for carbon ions).
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and Paganetti 2011), which were considered in the physical model used by the TPS. The AIC 
values found for the assumption RBE = 1.1 are higher than for the variable RBE model (see 
table 3) in the target, while they were similar for the bladder. Overall, considering both target 
and bladder, AIC values would support the adoption of a variable RBE in proton TP.
In the case of carbon ion treatments, the RBE and the corresponding RWD in the target, 
evaluated from the cMKM1/cMKM2 with parameters optimized to reproduce the clinically 
observed tumor control, are substantially lower than the RBE and RWD used in the reference 
TP (Okada et al 2012). This indicates that an overestimation of the equivalent dose results 
from the use of in vitro radiobiological parametrization in the TPS. The situation is inverted 
in the bladder, where an underestimation from the use of in vitro radiobiological parametriza-
tion was observed. Furthermore, a slightly non-uniform RWD in the target was also found in 
the re-planned treatments, in particular in the case of cMKM1, owing to the different RBE-
LETd dependence obtained using the optimized radiobiological parameters with respect to 
the reference one used in inverse planning. From a modeling point of view, this is due to the 
fact that the TCP model used was strictly coupled with the RBE-LETd modelization. Hence, 
not only the average RBE, but also the specific three-dimensional RBE distribution is directly 
dependent on the average clinical outcome. This also suggests the risk of a sub-optimal dose 
distribution in the target and the possibility of increasing the TCP via a proper radiobiological 
parametrization in the planning phase.
4.2. Radiobiological parameters
In the case of proton-based RT the radiobiological parameters obtained for the LM, reported 
in table  3, show similar trends to those reported in Carabe et al (2012) and Wilkens and 
Oelfke (2005), where the values were obtained fitting in vitro survival data using similar linear 
models. However, in some cases the values are different, in particular the parameter m, that 
Figure 10. NTCP as a function of dose per fraction (with constant total dose), predicted 
for carbon ion treatments using cMKM1 and cMKM2. The curves represent treatments 
with the same total dose. Experimental observations are also reported in the same plot.
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describe the LETd dependence. The m found in these works (0.01 < m < 0.02 µm keV−1Gy−1) 
is higher than the ones found with our clinical inference (m = 0.0034 µm keV−1Gy−1 for the 
CTV and m = 0.0054 µm keV−1Gy−1 for the bladder). In the case of the LM2 we obtained 
similar AIC ranking for models that discriminate the parameter m among different tissues 
(CTV and bladder) and those that use a unique m, confirming the approximation used in Frese 
et al (2011). However, a limited clinical data set was used in our analysis and it is likely that a 
better discrimination will be feasible as more data is included in the future.
In the case of carbon-based RT, negative β values were found in the bladder when apply-
ing the cMKM2 model, with the upper extremum of 95% CI greater than zero. The obtained 
results are consistent with the available clinical data (see for example figure 10, where the 
behavior of the NTCP against the dose per fraction is reported). AIC ranking supports such 
a result, providing lower values for cMKM2 with respect to the cMKM1 (where β = βX > 0) 
(see table 4). These values could be due to the heterogeneous cohort included in the two stud-
ies, with one population more radiosensitive than the other, as reported in Okada et al (2012). 
Additional trials could improve the accuracy of predicted β value and its CI.
It is worth noting that these estimates, in particular the RBE, are strongly dependent on the 
choice of the reference radiation parameters. Our choice was derived from literature (Mavroidis 
et al 2013) and reference therein. Since these parameters have been fitted over a popula-
tion response, it could be conceptually incorrect to directly use them in an individual model 
(Schinkel et al 2007, Stavrev et al 2010); however, we assumed that they were not too dissimi-
lar to the putative individual ones in the range of the phenomenological estimates and in the 
clinically-relevant dose range. Some of these parameters, such as the clonogen density, related 
to parameter γ and the seriality parameter s, were also assumed to be radiation independent. 
However this independence could be an approximation, since the mechanistic reasoning behind 
the model may be incorrect (Stavreva and Stavrev 2002, AAPM 2012) and these functions are 
generally used to fit the data phenomenologically. Other parameters, e.g. the ratio R = αX/βX, 
play a central role in both the evaluation of the response to x-rays and ion irradiation, the latter 
in terms of the RBE (Dale and Jones 1999, Carabe-Fernandez et al 2007). In general, these 
parameters present wide CI, as reported in Bentzen and Ritter (2005), where for the prostate 
R ∈ [−3.3, 5.6] Gy. Our results suggest a possible general method to determine the radiobio-
logical parameters with smaller CIs for both ion and photon-based treatments, by adding fur-
ther constraints to x-ray parametrization from the clinical data of ion treatments and vice versa.
4.3. Degeneration and CI
Currently, the applicability of the proposed approach is limited to the low number of available 
clinical trials and also in terms of low heterogeneity of the adopted fractionation schemes 
and beam setups (Goitein 2010, Suit et al 2010, Jensen et al 2011). This translates into high 
CIs and a possible degeneration of the estimated parameters. In fact, the large CIs observed 
may be reduced by increasing the difference in dose per fraction of the considered trials. In 
the panel (e) of figure 8 is shown the shrinking of the CR that can be achieved considering 
two carbon ion-based trials, one clinical, corresponding to a Df = 3.15 Gy(RBE) and the other 
fictitious, with Df = 8 Gy(RBE).
In general, the degeneration and the large CI issues could be solved by using the Bayesian 
framework as described above (equation (14)). The Bayesian framework also ensures a more 
robust evaluation of the radiobiological parameters, by starting from the in vitro experi-
ence and then adapting in an incremental manner to the clinical evidence as additional data 
become available.
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Finally, the possibility to use each plan of the treated patients in the cohort directly, will 
permit equation (7) to be used, thus avoiding the need to assume a representative patient set 
and to fit average quantities. This strategy will eventually solve the degeneration problem.
4.4. Clinical routine aspects
Remarkably, the proposed procedure does not affect the standard clinical workflow of TP. In 
other words, it is still possible to use the RBE and the corresponding RWD as reference quan-
tities within TP. However, the models would employ the radiobiological parameters directly 
inferred from actual clinical outcomes, thereby allowing a more reliable prediction of the 
clinical response after ion irradiation. In particular, this approach permits the identification 
of the proper clinical CR of the parameters and the CI of the derived quantities and hence 
represents a more robust strategy than the commonly used in vitro/in vivo extrapolations for 
the analysis of the radiobiological uncertainties and their impact in TP (Böhlen et al 2012, 
Friedrich et al 2013).
As indicated in AAPM (2012), biological models can be used for both plan optimiza-
tion and evaluation. Both tasks are closely related; however their predictive power may dif-
fer depending on whether they are used for plan optimization or for plan evaluation. This 
approach is an attempt to overcome the generic RBE models commonly used to steer the plan 
optimization process, towards the implementation of more predictive models to be used for 
dose-response evaluation and thus to guide the clinical strategy.
5. Conclusions
An alternative approach to radiobiological modelling in TP with proton and carbon ion beams 
has been discussed in this paper. The proposed approach reduces the need to use a reference 
radiation and/or parameters carried out from in vitro/in vivo studies, since the evaluated absolute 
biological effect, estimated at the voxel level from TP dose and LET distributions, is directly 
linked to the clinical outcome. This suggests the possibility of improving the 3D dose distribu-
tions in TP using more reliable radiobiological parameters, which can be derived directly from 
the observed clinical data. Of note, the investigated procedure uses a LETd-based modelization, 
thus reducing the complexity and overall computational cost required to perform the analysis 
with respect to approaches that rely on the knowledge of a full LET spectra.
To illustrate the general principle of the proposed approach, we estimated the radiobio-
logical parameters of the LETd-based models, using imaging and contouring from six rep-
resentative patients, the calculated doses and LETs based on three published schedules for 
prostate cancer patients and their related clinical outcomes. In the case of protons, an average 
RBE = 1.1 was found, consistently with current usage. However, the re-calculation of the 
treatment plans using an optimized set of radiobiological parameters obtained for protons and 
carbon ions clearly showed that the reference plan systematically over- and under-predicts the 
equivalent dose in the target and bladder, respectively.
The models presented do not account for any inherent inter-patient or intra-organ radiosen-
sitivity variations in their present form, or for tumour cell proliferation or tissue oxygenation, 
or other clinical factors influencing control and complications, such as concurrent chemo-
therapy, patients age and preexisting medical conditions. Nevertheless, the proposed method 
is general and can be extended to include all the above variables.
The major limitation of this method is the lack of available clinical data, in terms of quan-
tity and diversification in schedules and beam setups. However, parameter estimates can be 
A Cometto et al
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easily refined as additional follow-up data become available. A predictive analysis of the 
model is ongoing in a prospective study on an independent patient population, in order to test 
the ability of the model to predict the response in new patients.
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